NASDAQ:IFRX - Inflarx Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $28.75 -0.65 (-2.21 %) (As of 12/12/2018 12:43 PM ET)Previous Close$29.40Today's Range$28.55 - $30.0852-Week Range$17.50 - $42.83Volume4,451 shsAverage Volume43,131 shsMarket Capitalization$698.09 millionP/E Ratio-9.78Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases. It also develops IFX-2 for the treatment of chronic inflammation and autoimmune diseases. The company has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany. Receive IFRX News and Ratings via Email Sign-up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IFRX Previous Symbol CUSIPN/A Webwww.inflarx.de Phone49-36-4150-8180 Debt Debt-to-Equity RatioN/A Current Ratio18.71 Quick Ratio18.71 Price-To-Earnings Trailing P/E Ratio-9.78 Forward P/E Ratio-22.12 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.77 per share Price / Book4.98 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees21 Outstanding Shares23,410,000Market Cap$698.09 million OptionableNot Optionable Inflarx (NASDAQ:IFRX) Frequently Asked Questions What is Inflarx's stock symbol? Inflarx trades on the NASDAQ under the ticker symbol "IFRX." How were Inflarx's earnings last quarter? Inflarx NV (NASDAQ:IFRX) released its earnings results on Thursday, August, 9th. The company reported ($0.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.24. View Inflarx's Earnings History. When is Inflarx's next earnings date? Inflarx is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for Inflarx. What price target have analysts set for IFRX? 6 equities research analysts have issued 1-year target prices for Inflarx's shares. Their forecasts range from $40.00 to $55.00. On average, they anticipate Inflarx's stock price to reach $45.50 in the next twelve months. This suggests a possible upside of 58.3% from the stock's current price. View Analyst Price Targets for Inflarx. What is the consensus analysts' recommendation for Inflarx? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inflarx in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inflarx. Has Inflarx been receiving favorable news coverage? News headlines about IFRX stock have trended positive recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Inflarx earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. Who are some of Inflarx's key competitors? Some companies that are related to Inflarx include Ascendis Pharma A/S (ASND), Allakos (ALLK), Endo International (ENDP), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Xencor (XNCR), Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), Endocyte (ECYT), AnaptysBio (ANAB), Supernus Pharmaceuticals (SUPN) and Pacira Pharmaceuticals (PCRX). Who are Inflarx's key executives? Inflarx's management team includes the folowing people: Dr. Niels C. Riedemann M.D., Ph.D., Co-Founder, CEO & Exec. Director (Age 46)Prof. Renfeng Guo, Co-Founder, Chief Scientific Officer & Exec. Director (Age 48)Mr. Arnd Christ, Chief Financial Officer (Age 52)Mr. Jordan Silverstein, Head of Corp. Devel. & StrategyDr. Maria Habel PH.D., Head of Preclinical R&D (Age 36) When did Inflarx IPO? (IFRX) raised $100 million in an IPO on Wednesday, November 8th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are Inflarx's major shareholders? Inflarx's stock is owned by a number of of institutional and retail investors. Top institutional investors include Redmile Group LLC (8.65%), Scopia Capital Management LP (0.88%), Baker BROS. Advisors LP (0.76%), Vanguard Group Inc. (0.69%), Citadel Advisors LLC (0.34%) and Renaissance Technologies LLC (0.08%). Which major investors are selling Inflarx stock? IFRX stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Baker BROS. Advisors LP and Redmile Group LLC. Which major investors are buying Inflarx stock? IFRX stock was acquired by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Vanguard Group Inc., Renaissance Technologies LLC, Jane Street Group LLC, Bank of New York Mellon Corp, Matisse Capital and JPMorgan Chase & Co.. How do I buy shares of Inflarx? Shares of IFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Inflarx's stock price today? One share of IFRX stock can currently be purchased for approximately $28.75. How big of a company is Inflarx? Inflarx has a market capitalization of $698.09 million. The company earns $-27,390,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Inflarx employs 21 workers across the globe. What is Inflarx's official website? The official website for Inflarx is http://www.inflarx.de. How can I contact Inflarx? Inflarx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The company can be reached via phone at 49-36-4150-8180. MarketBeat Community Rating for Inflarx (NASDAQ IFRX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 94 (Vote Outperform)Underperform Votes: 113 (Vote Underperform)Total Votes: 207MarketBeat's community ratings are surveys of what our community members think about Inflarx and other stocks. Vote "Outperform" if you believe IFRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IFRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: How is the S&P 500 index different from the DJIA?